See more : Treace Medical Concepts, Inc. (TMCI) Income Statement Analysis – Financial Results
Complete financial analysis of Precision BioSciences, Inc. (DTIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precision BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Silver Lake Resources Limited (SLR.AX) Income Statement Analysis – Financial Results
- Axcap Ventures Inc. (GARLF) Income Statement Analysis – Financial Results
- Zoom2u Technologies Limited (Z2U.AX) Income Statement Analysis – Financial Results
- Labor Smart, Inc. (LTNC) Income Statement Analysis – Financial Results
- Ottawa Bancorp, Inc. (OTTW) Income Statement Analysis – Financial Results
Precision BioSciences, Inc. (DTIL)
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.73M | 25.10M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
| Cost of Revenue | 8.26M | 9.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 40.47M | 16.09M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
| Gross Profit Ratio | 83.06% | 64.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 53.38M | 83.94M | 115.24M | 98.06M | 82.42M | 45.12M | 20.32M | 9.10M |
| General & Administrative | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 6.10M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -9.76M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.20M |
| Cost & Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.84M |
| Interest Income | 7.69M | 3.47M | 208.00K | 822.00K | 4.27M | 1.88M | 872.00K | 570.00K |
| Interest Expense | 2.23M | 1.11M | 132.00K | 0.00 | 182.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.26M | 9.00M | 10.20M | 9.81M | 5.32M | 2.35M | 1.44M | 640.00K |
| EBITDA | -32.04M | -62.79M | -20.27M | -99.19M | -87.38M | -43.68M | -20.42M | -8.19M |
| EBITDA Ratio | -65.76% | -392.35% | -24.94% | -408.45% | -392.92% | -418.62% | -313.12% | -116.72% |
| Operating Income | -43.74M | -100.37M | -39.40M | -109.83M | -87.20M | -47.91M | -21.97M | -8.83M |
| Operating Income Ratio | -89.76% | -399.90% | -34.11% | -452.25% | -392.14% | -440.25% | -338.90% | -125.84% |
| Total Other Income/Expenses | 1.21M | 27.46M | 8.80M | 822.00K | -5.67M | 1.88M | 872.00K | 572.00K |
| Income Before Tax | -42.53M | -111.64M | -30.60M | -109.01M | -92.88M | -46.04M | -21.10M | -8.26M |
| Income Before Tax Ratio | -87.28% | -444.80% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.69% |
| Income Tax Expense | 0.00 | 11.27M | 316.00K | 10.43M | -9.58M | 1.88M | -754.00K | -5.00K |
| Net Income | -61.32M | -122.91M | -30.92M | -109.01M | -83.30M | -46.04M | -21.10M | -8.25M |
| Net Income Ratio | -125.84% | -489.71% | -26.76% | -448.86% | -374.59% | -423.02% | -325.45% | -117.62% |
| EPS | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
| EPS Diluted | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
| Weighted Avg Shares Out | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
| Weighted Avg Shares Out (Dil) | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Precision BioSciences to Participate in Upcoming November Investor Conferences
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
Precision BioSciences to Report Third Quarter Results on November 4, 2024
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
Source: https://incomestatements.info
Category: Stock Reports